Haimin Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Haimin Song has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Chuan Zeng
The First Clinical Medical College of Gannan Medical University, Ganzhou City, China
3 shared publicationsTao Long
Department of Neurosurgery, First Affiliated Hospital of Gannan Medical University
3 shared publicationsChunming He
Department of Neurosurgery, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China
2 shared publications- Chunming He
Department of Neurosurgery, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi 341000, China
2 shared publications Huaiyu Zhou
Department of Neurosurgery, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi 341000, China; The First Clinical Medical College of Gannan Medical University, Ganzhou, Jiangxi 341000, China
2 shared publicationsPeng Xiong
The First Clinical Medical College of Gannan Medical University, Ganzhou City, China
2 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1916071
Exploring the causal role and mechanism of galanin in glioblastoma: integration of mendelian randomization, network analysis, molecular docking and experimental validation
Background: Glioblastoma (GBM) is a highly malignant central nervous system tumor with an exceptionally poor prognosis. The neuropeptide Galanin is implicated in GBM development, but its specific molecular mechanisms and therapeutic potential remain unclear. In this study, we integrate Mendelian randomization (MR) and network toxicology approaches to systematically characterize the pharmacological activity and mechanistic underpinnings of Galanin in GBM. Methods: A two-sample MR analysis was employed to investigate the causal relationship between Galanin and GBM risk. Galanin-related targets and differentially expressed genes were screened from public databases. Prognostic genes were identified through protein-protein interaction networks, single-cell sequencing, and the LASSO-COX model, and binding activity was validated by molecular docking. Finally, target genes were silenced using siRNA, and qRT-PCR, CCK-8, and colony formation assays were performed to validate the regulatory roles of CCNA2 and SERPINA1 in GBM cell proliferation. Results: The MR analysis confirmed a causal association between Galanin and GBM risk. Multidimensional bioinformatics identified four core genes: CCNA2, BRCA1, SERPINA1, and LGALS3. Molecular docking confirmed stable binding of Galanin to the proteins encoded by these genes. In vitro experiments demonstrated that silencing CCNA2 or SERPINA1 effectively inhibits GBM cell proliferation and colony formation. Conclusion: This study provides a comprehensive analysis of the regulatory mechanisms of Galanin in GBM from both genetic and computational toxicology perspectives. Our findings indicate that Galanin modulates CCNA2, BRCA1, SERPINA1, and LGALS3, likely through mediating the PI3K-Akt and focal adhesion signaling pathways, thereby hindering tumor progression. These results provide a foundational rationale for Galanin-targeted therapeutic strategies in GBM. Furthermore, the in vitro experiments corroborate that CCNA2 and SERPINA1 promote tumor cell proliferation, positioning them as promising therapeutic targets for GBM.
- 4 August 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1916071
Open AccessExploring the causal role and mechanism of galanin in glioblastoma: integration of mendelian randomization, network analysis, molecular docking and experimental validation
Background: Glioblastoma (GBM) is a highly malignant central nervous system tumor with an exceptionally poor prognosis. The neuropeptide Galanin is implicated in GBM development, but its specific molecular mechanisms and therapeutic potential remain unclear. In this study, we integrate Mendelian randomization (MR) and network toxicology approaches to systematically characterize the pharmacological activity and mechanistic underpinnings of Galanin in GBM. Methods: A two-sample MR analysis was employed to investigate the causal relationship between Galanin and GBM risk. Galanin-related targets and differentially expressed genes were screened from public databases. Prognostic genes were identified through protein-protein interaction networks, single-cell sequencing, and the LASSO-COX model, and binding activity was validated by molecular docking. Finally, target genes were silenced using siRNA, and qRT-PCR, CCK-8, and colony formation assays were performed to validate the regulatory roles of CCNA2 and SERPINA1 in GBM cell proliferation. Results: The MR analysis confirmed a causal association between Galanin and GBM risk. Multidimensional bioinformatics identified four core genes: CCNA2, BRCA1, SERPINA1, and LGALS3. Molecular docking confirmed stable binding of Galanin to the proteins encoded by these genes. In vitro experiments demonstrated that silencing CCNA2 or SERPINA1 effectively inhibits GBM cell proliferation and colony formation. Conclusion: This study provides a comprehensive analysis of the regulatory mechanisms of Galanin in GBM from both genetic and computational toxicology perspectives. Our findings indicate that Galanin modulates CCNA2, BRCA1, SERPINA1, and LGALS3, likely through mediating the PI3K-Akt and focal adhesion signaling pathways, thereby hindering tumor progression. These results provide a foundational rationale for Galanin-targeted therapeutic strategies in GBM. Furthermore, the in vitro experiments corroborate that CCNA2 and SERPINA1 promote tumor cell proliferation, positioning them as promising therapeutic targets for GBM.
- 5 December 2024
- Published by Springer Nature in Child's Nervous System
- Vol. 41 (1) , 1-10
Bibliometric analysis of the top 100 most cited articles on the immunotherapy for glioblastoma
Background The nature of immunotherapy has rendered it a focal point in the management of glioblastoma (GBM). This bibliometric analysis aimed to analyze the top 100 most cited articles about immunotherapy for GBM to expand the knowledge of research related to this therapeutic approach. Methods The retrieval of the top 100 articles on “Immunotherapy AND Glioblastoma” was performed using the Web of Science Core Collection database. Relevant details were extracted for bibliometric analysis, and to gain insights, a comparison was made between older and newer articles. Categorical data underwent analysis utilizing Pearson’s chi-square test, while continuous data were analyzed using the Wilcoxon rank-sum test. Results The top 100 articles were distributed across the years 2000 to 2021, with the number of citations ranging from 135 to 1058. Among these articles, publications peaked in 2017 and 2018 (n = 12), and the most common country of correspondence was the USA (n = 73). Clinical Cancer Research was the most cited journal, and authors SAMPSON JH and LIM M had the highest number of papers (n = 6). Newer articles had significantly higher citation rates (p < 0.01), more authors (p < 0.05), more institutes (p < 0.01), and more collaborations between institutions (p < 0.01). Subspecialties showed a trend of more “TME” (1% vs 7%, p = 0.05945) in the before and after group comparison, although this difference was not statistically significant (p > 0.05). Conclusion The study of the top 100 cited articles on immunotherapy for GBM shows that researchers are actively working together to develop novel approaches to GBM immunotherapy. The high citations, leading countries, journals, and authors, along with evolving research characteristics, indicate a field with great interest and potential. Immunotherapy holds significant promise in GBM treatment.
- 5 December 2024
- Published by Springer Nature in Child's Nervous System
- Vol. 41 (1) , 1-10
Bibliometric analysis of the top 100 most cited articles on the immunotherapy for glioblastoma
Background The nature of immunotherapy has rendered it a focal point in the management of glioblastoma (GBM). This bibliometric analysis aimed to analyze the top 100 most cited articles about immunotherapy for GBM to expand the knowledge of research related to this therapeutic approach. Methods The retrieval of the top 100 articles on “Immunotherapy AND Glioblastoma” was performed using the Web of Science Core Collection database. Relevant details were extracted for bibliometric analysis, and to gain insights, a comparison was made between older and newer articles. Categorical data underwent analysis utilizing Pearson’s chi-square test, while continuous data were analyzed using the Wilcoxon rank-sum test. Results The top 100 articles were distributed across the years 2000 to 2021, with the number of citations ranging from 135 to 1058. Among these articles, publications peaked in 2017 and 2018 (n = 12), and the most common country of correspondence was the USA (n = 73). Clinical Cancer Research was the most cited journal, and authors SAMPSON JH and LIM M had the highest number of papers (n = 6). Newer articles had significantly higher citation rates (p < 0.01), more authors (p < 0.05), more institutes (p < 0.01), and more collaborations between institutions (p < 0.01). Subspecialties showed a trend of more “TME” (1% vs 7%, p = 0.05945) in the before and after group comparison, although this difference was not statistically significant (p > 0.05). Conclusion The study of the top 100 cited articles on immunotherapy for GBM shows that researchers are actively working together to develop novel approaches to GBM immunotherapy. The high citations, leading countries, journals, and authors, along with evolving research characteristics, indicate a field with great interest and potential. Immunotherapy holds significant promise in GBM treatment.
- Open Access
- 12 November 2024
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 287, 117311
Combining mendelian randomization analysis and network toxicology strategy to identify causality and underlying mechanisms of environmental pollutants with glioblastoma: A study of Methyl-4-hydroxybenzoate
- 12 November 2024
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 287, 117311
Open AccessCombining mendelian randomization analysis and network toxicology strategy to identify causality and underlying mechanisms of environmental pollutants with glioblastoma: A study of Methyl-4-hydroxybenzoate
- Open Access
- 30 October 2024
- Published by Elsevier in World Neurosurgery
- Vol. 193, 747-753
Traumatic Brain Injury Increasing Risk of Meningioma? From the Genetic Evidence
- 30 October 2024
- Published by Elsevier in World Neurosurgery
- Vol. 193, 747-753
Open AccessTraumatic Brain Injury Increasing Risk of Meningioma? From the Genetic Evidence
- Top Cited PapersOpen Access
- 18 December 2023
- Published by Springer Nature in BMC Genomics
- Vol. 24 (1) , 1-17
Investigating the causal impact of gut microbiota on glioblastoma: a bidirectional Mendelian randomization study
Background: Currently, the influence of microbiota on the occurrence, progression, and treatment of cancer is a topic of considerable research interest. Therefore, based on the theory of the gut-brain axis proved by previous studies, our objective was to uncover the causal relationship between glioblastoma and the gut microbiome using Mendelian randomization analysis. Methods: We conducted a bidirectional Mendelian randomization study using summary statistics of gut microbiota derived from the MiBioGen consortium, the largest database of gut microbiota. Summary statistics for glioblastoma were obtained from IEU OpenGWAS project, which included 91 cases and 218,701 controls. We assessed the presence of heterogeneity and horizontal pleiotropy in the analyzed data. We primarily employed the inverse variance weighting method to investigate the causal relationship between gut microbiota and glioblastoma after excluding cases of horizontal pleiotropy. Four other analysis methods were employed as supplementary. Excluding abnormal results based on leave-one-out sensitivity analysis. Finally, reverse Mendelian randomization analysis was performed. Results: Four genus-level taxa and one family-level taxa exhibited causal associations with glioblastoma. And these results of reverse Mendelian randomization analysis shown glioblastoma exhibited causal associations with three genus-level taxa and one family-level taxa. However, the Prevotella7(Forward, P=0.006, OR=0.34, 95%CI:0.158-0.732; Reverse, P=0.004, OR=0.972, 95%CI:0.953-0.991) shown the causal associations with glioblastoma in the bidirectional Mendelian randomization. Conclusions: In this bidirectional Mendelian randomization study, we identified five gut microbiota species with causal associations to glioblastoma. However, additional randomized controlled trials are required to clarify the impact of gut microbiota on glioblastoma and to reveal its precise mechanisms.
- 18 December 2023
- Published by Springer Nature in BMC Genomics
- Vol. 24 (1) , 1-17
Top Cited PapersOpen AccessInvestigating the causal impact of gut microbiota on glioblastoma: a bidirectional Mendelian randomization study
Background: Currently, the influence of microbiota on the occurrence, progression, and treatment of cancer is a topic of considerable research interest. Therefore, based on the theory of the gut-brain axis proved by previous studies, our objective was to uncover the causal relationship between glioblastoma and the gut microbiome using Mendelian randomization analysis. Methods: We conducted a bidirectional Mendelian randomization study using summary statistics of gut microbiota derived from the MiBioGen consortium, the largest database of gut microbiota. Summary statistics for glioblastoma were obtained from IEU OpenGWAS project, which included 91 cases and 218,701 controls. We assessed the presence of heterogeneity and horizontal pleiotropy in the analyzed data. We primarily employed the inverse variance weighting method to investigate the causal relationship between gut microbiota and glioblastoma after excluding cases of horizontal pleiotropy. Four other analysis methods were employed as supplementary. Excluding abnormal results based on leave-one-out sensitivity analysis. Finally, reverse Mendelian randomization analysis was performed. Results: Four genus-level taxa and one family-level taxa exhibited causal associations with glioblastoma. And these results of reverse Mendelian randomization analysis shown glioblastoma exhibited causal associations with three genus-level taxa and one family-level taxa. However, the Prevotella7(Forward, P=0.006, OR=0.34, 95%CI:0.158-0.732; Reverse, P=0.004, OR=0.972, 95%CI:0.953-0.991) shown the causal associations with glioblastoma in the bidirectional Mendelian randomization. Conclusions: In this bidirectional Mendelian randomization study, we identified five gut microbiota species with causal associations to glioblastoma. However, additional randomized controlled trials are required to clarify the impact of gut microbiota on glioblastoma and to reveal its precise mechanisms.